Malignant Pleural Effusion Clinical Trial
Official title:
Activity Behaviours in Patients With Malignant Pleural Effusion: Relationships With Quality of Life, and Respiratory Symptoms, and Survival
The purpose of this research is to objectively assess activity behaviours (i.e., physical activity and sedentary behaviour) in patients with malignant pleural effusion. First, we aim to describe the physical activity and sedentary behavior of patients with MPE in Hong Kong. Secondarily, we aim to assess the relationships between activity behaviours and survival, quality of life, and respiratory symptoms e.g. shortness of breath.
The development of a malignant pleural effusion (MPE) can be a consequence of metastatic
spread of any cancer, but most commonly lung, breast and gynecological cancers or from
primary pleural neoplasms (e.g., mesothelioma). The presence of MPE represents incurable
disease and median survival ranges from 3 to 12 months from first presentation.
Breathlessness is a common and debilitating symptom reported by this patient group and
interventions are aimed at managing symptoms for optimal quality of life.
Breathlessness and other symptoms that result from MPE are likely to limit a person's ability
to be physically active. Activity behaviours encompasses physical activity behaviour (i.e.,
low intensity physical activity and moderate-to-vigorous physical activity) and sedentary
behaviour (i.e., sitting or reclining activities low in energy expenditure) accumulated
during waking hours. Performance status measures are routinely used in cancer populations and
are largely based on self-reported activity behaviors. While performance status is a reliable
predictor of survival in patients with MPE, such measures are subjective, broad and
significantly, can differ between patients and clinicians. Measures of performance status may
fail to detect small, but meaningful changes in activity behaviours. Objective assessment of
activity behaviours using accelerometers could provide a more reliable and sensitive method
to assess physical activity and sedentary behaviour, particularly in advanced cancer
populations. Objective assessment of activity behaviours using accelerometers has been
demonstrated to accurately measure physical activity when compared to oxygen consumption.
Triaxial accelerometry is considered the most accurate assessment for physical activity in
chronic disease populations.
Preliminary research in patients with MPE indicates that patients have very low activity
levels. Participants with MPE spent more that 70% of waking hours sedentary (i.e., activities
of very low energy expenditure, sitting or lying down). Those patients with MPE with the best
performance status and longest survival were significantly more active and less sedentary
than those with a poor performance status and limited survival. However, these preliminary
results require replication. Further, it is not yet known if activity behaviours are
associated with quality of life or symptoms such as dyspnea in this patient population.
Evidence from other cancer survivor populations suggests that activity behaviours are linked
to quality of life and symptoms. In patients with breast, colorectal, lung and ovarian
cancer, those that are more physically active report better quality of life. In patients with
lung cancer, symptoms such as breathlessness and fatigue appear to be associated with lower
physical activity levels.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT04793607 -
Interventions for Malignant Pleural Effusions Impact on Fatigue
|
||
Recruiting |
NCT03987087 -
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT02942043 -
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01997190 -
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT00564733 -
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04131231 -
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
|
N/A | |
Completed |
NCT02674243 -
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
|
Phase 3 | |
Terminated |
NCT01004510 -
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00313066 -
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
|
Phase 4 | |
Terminated |
NCT04236037 -
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
|
N/A | |
Completed |
NCT05372055 -
Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
|
||
Not yet recruiting |
NCT04914598 -
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
|
Phase 3 | |
Recruiting |
NCT04322136 -
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT03973957 -
Talc Outpatient Pleurodesis With Indwelling Catheter
|
N/A | |
Recruiting |
NCT05923515 -
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT02649894 -
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
|
N/A | |
Recruiting |
NCT03403855 -
Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients
|
N/A |